ClinicalTrials.gg
CompletedNCT07223216Updated Oct 27, 2026

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

A Phase 1 interventional study of BMF-650 in Obesity, sponsored by Biomea Fusion Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Biomea Fusion Inc. · Phase 1, Interventional, and Treatment

Updated Oct 27, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.

Read the detailed description

This is a single center, double-blind, randomized, placebo-controlled, first-in-human (FIH) study of BMF-650, an oral non-peptide GLP-1 receptor agonist administered to otherwise healthy overweight or obese participants. Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.

02

Conditions studied

  • Obesity

Keywords

  • Obesity
  • Obese
  • Overweight
  • Weight-loss
  • GLP-1
  • GLP-1 agonist
  • GLP-1 receptor agonist
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 90 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Biomea Fusion Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Must be able to understand a written , which must be obtained prior to initiation of study procedures.
  2. Must be willing and able to comply with all study requirements
  3. Healthy males or non-pregnant, non-lactating healthy females with obesity or overweight.
  4. For Part 1 (SAD cohorts), of 25.0 to 40.0 kg/m2 as measured at screening, with no chronic health conditions.
  5. For Part 2 (MAD cohorts), BMI of 30.0 to 45.0 kg/m2, as measured at screening with no chronic health conditions.
  6. Have a stable body weight (less than or equal to 5% body weight gain or loss) for 3 months prior to screening.
  7. ≤ 6.5% at screening

Key Exclusion Criteria:

Medical/Surgical History and Mental Health

  1. Known self or family history (first-degree relative) of medullary thyroid cancer and/or multiple endocrine neoplasia Type 2 (MEN2).
  2. History of stomach or intestinal surgery or resection and/or gastroparesis (except that appendectomy and/or hernia repair will be allowed).
  3. Significant history of or currently have major depressive disorder or psychiatric disorder or suicidal ideation within the last 2 years.
  4. Severe uncontrolled treated or untreated hypertension (systolic blood pressure [BP] >150 mmHg or diastolic BP >90 mmHg).
  5. Mean interval greater than 450 msec on triplicate ECGs.

    Diagnostic Assessments

  6. abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator
  7. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) antibody results.
  8. of \<60 mL/min/1.73 m2
  9. , ALT or total >
  10. Lipase and/or amylase > ULN
  11. Calcitonin ≥20 ng/L

    Prior Study Participation

  12. Participants who have received any IMP in a clinical research study within 5 half -lives or within 30 days prior to first dose

    Prior and Concomitant Medication

  13. Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than HRT/hormonal ) in the 14 days before first IMP administration
  14. Use of prescription or over-the-counter medications known to significantly prolong the QT or QTc interval is excluded.
  15. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management
  16. Participants who have previously used GLP-1 receptor agonist, or GIP/GLP-1 dual receptor agonists, or any medicine containing a GLP-1 and/or GIP receptor agonist in the 6 months prior to first IMP administration
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Part 1 SAD Cohort 1 (Regimen A)

    BMF-650 Tablets 10 mg or matching placebo in fasted state

    Drug: BMF-650

  • Experimental
    Part 1 SAD Cohort 2 (Regimen B and C)

    Regimen B: BMF-650 Tablets 25 mg or matching placebo in fasted state Regimen C: BMF-650 Tablets 25 mg or matching placebo in fed state (high-fat breakfast 30 minutes before BMF-650 or placebo is administered)

    Drug: BMF-650

  • Experimental
    Part 1 SAD Cohort 3 (Regimen D)

    BMF-650 Tablets 50 mg or matching placebo in fasted state

    Drug: BMF-650

  • Experimental
    Part 1 SAD Cohort 4 (Regimen E and F)

    Regimen E: BMF-650 Tablets 100 mg or matching placebo in fasted state Regimen F: BMF-650 Tablets 100 mg or matching placebo in fed state (high-fat breakfast 30 minutes before BMF-650 or placebo is administered)

    Drug: BMF-650

  • Experimental
    Part 1 SAD Cohort 5 (Regimen G)

    BMF-650 Tablets 200 mg or matching placebo in fasted state

    Drug: BMF-650

  • Experimental
    Part 2 MAD Cohort 1 (Regimen H)

    BMF-650 Tablets or matching placebo in fasted state 10 mg QD for 7 days; 25 mg QD for 7 days; 50 mg QD for 7 days; 100 mg QD for 21 days.

    Drug: BMF-650

  • Experimental
    Part 2 MAD Cohort 2 (Regimen I)

    BMF-650 Tablets or matching placebo in fasted state 50 mg QD for 7 days; 100 mg QD for 7 days; 200 mg QD for 28 days.

    Drug: BMF-650

  • Experimental
    Part 2 MAD Cohort 3 (Regimen J)

    BMF-650 Tablets or matching placebo in fasted state 75 mg QD for 7 days; 150 mg QD for 7 days; 300 mg QD for 28 days.

    Drug: BMF-650

  • Experimental
    Part 2 MAD Cohort 4 (Regimen K)

    BMF-650 Tablets or matching placebo in fasted state 75 mg QD for 7 days; 200 mg QD for 7 days; 400 mg QD for 28 days.

    Drug: BMF-650

  • Experimental
    Part 2 MAD Cohort 5 (Regimen L)

    BMF-650 Tablets or matching placebo in fasted state 200 mg QD for 7 days; 400 mg QD for 21 days

    Drug: BMF-650

Interventions

  • DrugBMF-650

    Interventional Product

06

What researchers measure

Primary outcomes

  1. Assess safety and tolerability of BMF-650

    Incidence of adverse events (AEs)

    Time frame: 6 weeks (Part 1) 4 and 11 weeks (Part 2 MAD Cohorts 1-4) and 6 weeks (Part 2 MAD Cohort 5)

  2. Assess safety and tolerability of BMF-650

    Vital signs like blood pressure

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  3. Assess safety and tolerability of BMF-650

    ECG measures like QTcF interval

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  4. Assess safety and tolerability of BMF-650

    Physical examinations like general appearance

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  5. Assess safety and tolerability of BMF-650

    Safety labs like clinical chemistry

    Time frame: 2 weeks (Part 1), 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

Secondary outcomes

  1. Evaluate PK and food effect of BMF-650 in fed and fasted states

    Tmax

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  2. Evaluate PK and food effect of BMF-650 in fed and fasted states

    Cmax

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4 ) and 4 weeks (Part 2 MAD Cohort 5)

  3. Evaluate PK and food effect of BMF-650 in fed and fasted states

    AUC(0-last)

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohort 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  4. Evaluate PK and food effect of BMF-650 in fed and fasted states

    AUC(0-inf)

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  5. Evaluate PK and food effect of BMF-650 in fed and fasted states

    T1/2

    Time frame: 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

  6. Assess the impact of multiple ascending doses of BMF-650 on weight (Part 2 only)

    Percent change in body weight compared to baseline

    Time frame: 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)

07

Study locations

1 site
  • Medpace Clinical Pharmacology
    Cincinnati, Ohio 45227, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Aug 2026, 9 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is close to that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion May 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
Oct 23, 2025
Primary completionActual
Aug 12, 2026was May 2026
CompletionActual
Aug 26, 2026was Jun 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Primary completion
May 2026→Aug 12, 2026 (actual)
Oct 27, 2026
Study completion
Jun 2026→Aug 26, 2026 (actual)
Oct 27, 2026
Enrollment
80 (estimated)→90 (actual)
Oct 27, 2026
Eligibility
1 criterion edited, 2 added
What changed in the criteria
  • AddedKey Inclusion Criteria:
  • EditedHbA1c ≤ 6.5% at screening
  • AddedKey Exclusion Criteria:
Oct 27, 2026
Interventions
Arm changed Part 1 SAD Cohort 4 (Regimen E and F) (Optional)→Part 1 SAD Cohort 4 (Regimen E and F); Part 1 SAD Cohort 5 (Regimen G) (Optional)→Part 1 SAD Cohort 5 (Regimen G); Part 2 MAD Cohort 4 (Regimen K) (Optional)→Part 2 MAD Cohort 4 (Regimen K). Arms added: Part 2 MAD Cohort 5 (Regimen L)
Oct 27, 2026
Primary outcomes
5 time frame changed
What changed in the outcomes
  • Time frameAssess safety and tolerability of BMF-6506 weeks (Part 1) and 11 weeks (Part 2) → 6 weeks (Part 1) 4 and 11 weeks (Part 2 MAD Cohorts 1-4) and 6 weeks (Part 2 MAD Cohort 5)
  • Time frameAssess safety and tolerability of BMF-650#26 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameAssess safety and tolerability of BMF-650#36 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameAssess safety and tolerability of BMF-650#46 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameAssess safety and tolerability of BMF-650#56 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1), 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
Oct 27, 2026
Secondary outcomes
6 time frame changed
What changed in the outcomes
  • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states2 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#22 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4 ) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#32 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohort 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#42 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#52 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
  • Time frameAssess the impact of multiple ascending doses of BMF-650 on weight (Part 2 only)6 weeks → 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Primary completion May 2026→Aug 12, 2026 (now actual)
    Study completion Jun 2026→Aug 26, 2026 (now actual)
    Enrollment 80 (estimated)→90 (actual)
    Eligibility 1 criterion edited, 2 added
    What changed in the criteria
    • AddedKey Inclusion Criteria:
    • EditedHbA1c ≤ 6.5% at screening
    • AddedKey Exclusion Criteria:
    Primary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameAssess safety and tolerability of BMF-6506 weeks (Part 1) and 11 weeks (Part 2) → 6 weeks (Part 1) 4 and 11 weeks (Part 2 MAD Cohorts 1-4) and 6 weeks (Part 2 MAD Cohort 5)
    • Time frameAssess safety and tolerability of BMF-650#26 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameAssess safety and tolerability of BMF-650#36 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameAssess safety and tolerability of BMF-650#46 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameAssess safety and tolerability of BMF-650#56 weeks (Part 1) and 11 weeks (Part 2) → 2 weeks (Part 1), 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    Secondary outcomes 6 time frame changed
    What changed in the outcomes
    • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states2 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#22 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4 ) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#32 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohort 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#42 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameEvaluate PK and food effect of BMF-650 in fed and fasted states#52 weeks (Part 1) and 6 weeks (Part 2) → 2 weeks (Part 1) 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    • Time frameAssess the impact of multiple ascending doses of BMF-650 on weight (Part 2 only)6 weeks → 4 and 6 weeks (Part 2 MAD Cohorts 1-4) and 4 weeks (Part 2 MAD Cohort 5)
    Interventions Arm changed Part 1 SAD Cohort 4 (Regimen E and F) (Optional)→Part 1 SAD Cohort 4 (Regimen E and F); Part 1 SAD Cohort 5 (Regimen G) (Optional)→Part 1 SAD Cohort 5 (Regimen G); Part 2 MAD Cohort 4 (Regimen K) (Optional)→Part 2 MAD Cohort 4 (Regimen K). Arms added: Part 2 MAD Cohort 5 (Regimen L)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07223216
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Oct 23, 2025
Primary completion
Aug 12, 2026
Completion
Aug 26, 2026
Last update
Oct 27, 2026

Study contacts

Biomea Fusion Inc.
study director · Biomea Fusion Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion